Apimeds Pharmaceuticals US (APUS) Capital Expenditures (2025)

Apimeds Pharmaceuticals US (APUS) reported Capital Expenditures of $21424.0 for Q4 2025, down 4.95% quarter-over-quarter from $22540.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Capital Expenditures (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Capital Expenditures for 1 years, with the latest figure at $21424.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	168.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	110.00 Mn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	100.80 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	9.10 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	51.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	4.09 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	8.83 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	2.04 Mn
10	Apimeds Pharmaceuticals US	13.93 Mn	10.29 Mn	-	21,424.00

Download Data